The use of antiviral drugs for influenza: A foundation document for practitioners

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 24, Issue 3, 2013, Pages

  Aoki, Fred Y ^a   Allen, Upton D ^b,c,d   Stiver, H Grant ^e   Evans, Gerald A ^f  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HYDRO QUÉBEC   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; PREDNISONE; RIBAVIRIN; ZANAMIVIR;

2009 H1N1 INFLUENZA; ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASTHMA; BRONCHOSPASM; CHEMOPROPHYLAXIS; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONFUSION; CONSCIOUSNESS DISORDER; CORTICOSTEROID THERAPY; COUGHING; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DEHYDRATION; DELIRIUM; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INTESTINE EPITHELIUM CELL; KIDNEY DYSFUNCTION; KIDNEY TUBULE EXCRETION; LABORATORY DIAGNOSIS; LARYNGOTRACHEOBRONCHITIS; LISTLESSNESS; LYMPHOCYTOPENIA; META ANALYSIS; META ANALYSIS (TOPIC); MYALGIA; NEUTROPENIA; NONHUMAN; OTITIS MEDIA; PANDEMIC INFLUENZA; PATIENT DECISION MAKING; PATIENT PREFERENCE; POST EXPOSURE PROPHYLAXIS; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY VIRUS; REYE SYNDROME; SEASONAL INFLUENZA; SINGLE DRUG DOSE; SORE THROAT; SWEAT; THORAX PAIN; VIRAL CLEARANCE; VIRUS PNEUMONIA;

EID: 84888153498     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/130913     Document Type: Article

References (101)

1. Aoki FY, Allen UD, Stiver HG, Evans GA. The use of antiviral drugs for influenza: Guidance for practitioners 2011-2012. http://www.ammi.ca/guidelines (Accessed October 11, 2013).
2. Aoki FY, Allen UD, Stiver HG, Evans GA. The use of antiviral drugs for influenza: Guidance for practitioners 2012-2013. Can J Inf Dis Med Microbio 2012; 23:e79-i92.
3. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: Systematic review and meta-analysis. BMJ 2009;339:b5106. DOI:10.1136/bmj.b5106.
4. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: A systemic review and meta-analysis of observational studies. Ann Int Med 2012; 156: 512-526.
5. American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004; 114;874-7.
6. FluWatch, August 12-25, 2012. Public Health Agency of Canada. http://www.phac-aspc.gc.ca/fluwatch/11-12/w34-12/pdf/fw2012-34- eng.pdf (Accessed October 11, 2013).
7. National Advisory Committee on Influenza (NACI). Statement on seasonal influenza vaccine 2012-2013. July 6, 2012. Available at: http://resources.cpha. ca/immunize.ca/data/1814e.pdf (Accessed October 11, 2013).
8. Influenza Antiviral Drug Resistance: Questions and Answers. Centers for Disease Control and Prevention (CDC) & National Center for Immunization and Respiratory Diseases (NCIRD), July 23, 2012. Available at: www.cdc.gov/flu/ about/qa/ antiviralresistamce.htm. (Accessed August 2012).
9. CDC. Seasonal Influenza. Available at: http://www.cdc.gov/flu/ about/qa/disease.htm (Accessed October 11, 2013).
10. Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. N Engl J Med 2010; 362: 1708-19.
11. Studahl M. Influenza and CNS manifestations J Clin Virol 2003; 28: 225-32.
12. National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2012- 2013. http://www.phac-aspc.gc.ca/ccdrw-rmtch/index-eng.php.
13. Blanton L, Peacock G, Cox C, et al. Neurologic disorders among pediatric deaths associated with the 2009 pandemic influenza. Pediatrics 2012; 130: 390-6.
14. Boivin G, Hardy J, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31: 1166-9.
15. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
16. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in the treatment of acute influenza: A randomized controlled trial. Neuraminidase Inhibitor Influenza Treatment Investigator Group. Lancet 2000; 355: 1845-50.
17. Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998; 15: 16-22.
18. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003; 36: 299-305.
19. Tamiflu, US Product Monograph. December 2012.
20. Aoki FY. Oseltamivir. In: Kucers' The Use of Antibiotics. 6th edn. Grayson ML, Crowe SM, McCarthy JS, et al, eds. Edward Arnold Publishers Ltd, London, UK, 2010, pp 3029-42.
21. Kawai, N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infection 2008; 56: 1-7.
22. Sugaya N, Tamara D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir virus infection in children. Clin Infect Dis 2008; 47: 339-45.
23. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43: 439-44.
24. American Academy of Pediatrics. Antiviral Drugs. In: Pickering LR, Baker CJ, Kimberlin DW, Long SS. Red Book 2012 Report of the Committee on Infectious Diseases, 29th edn. Elk Grove Village, IL. American Academy of Pediatrics, 2012, pp 845-7.
25. Thorne-Humphrey LM, Goralski KB, Slayter KC, et al. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO) trial. J Antimicrob Chemother 2011; 66: 2083-91.
26. Choo D, Hossain M, Liew P, et al. Side effects of oseltamivir in endstage renal failure patients. Nephrol Dialysis Transpl 2011; 26: 2339-44.
27. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med 2010; 38(4Suppl): 43-51.
28. Robson R, Buttimore A, Lynn K, et al. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2006; 21:2556-62
29. Schreuder, MF, van der Flier M, Knops NB, Koster-Kamphuis L, Brüggemann RJ. Oseltamivir dosing in children undergoing hemodialysis. Clin Infect Dis 2010; 50(10): 1427-1428.
30. Nicholson KG. Human influenza. In: Textbook of Influenza. Nicholson KG, Webster RG & Hay AJ, eds. Blackwell Science, London, UK, 1998, pp 219-64.
31. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships. Int J Risk Saf Med 2008; 20: 5-36.
32. Toovey S, Prinssen EP, Rayner CR, et al. Post-marketing assessment of neuropsychiatric adverse effects in influenza patients treated with oseltamivir: An updated review. Drug Safety 2008; 31: 1097-114.
33. Duval X, Vander Werf S, Bhanchan T, et al. Efficacy of oseltamivir-zanamivir combinations compared to each monotherapy for seasonal influenza: A randomized, placebocontrolled trial. PLoS Medicine 2010; 7:e1000362.
34. South East Asia Infectious Disease Clinical Research Network. High-dose versus standard-dose oseltamivir for the treatment of severe influenza. Abstract P-205. Options for the Control of Influenza VII. Hong Kong, SAR China, 3-7 September 2010.
35. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Can Med Assoc J 2010; 182: 357-63.
36. Whitley RJ, Young, N, Ipe D, et al. Safety and acceptability of oseltamivir liquid formulation in the treatment of influenza in children aged one to 12 years. In: 9th International Congress of Chemotherapy. Buenos Aires, 2000.
37. Wooltorton E. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. Can Med Assoc J 2004; 170:336.
38. U.S. Food and Drug Administration. Tamiflu Pediatric Adverse Events: Questions and Answers. Available at: http://www.fda.gov/cder/drug/ infopage/tamiflu/QA20051117.htm (Accessed October 11, 2013).
39. Truffa MM. One-Year Post Exclusivity Adverse Event Review for Tamiflu® (oseltamivir). Available at: http://www.fda.gov/ohrms/dockets/ ac/05/slides/2005-4180s-03-truffa.ppt (Accessed October 11, 2013).
40. Aoki FY. Zanamivir. In Kucer's The Use of Antibiotics, 6th edn. Grayson ML, Crowe SM, McCarthy JS, et al, eds. Edward Arnold Publishers Ltd, London, UK, 2010, pp 3013-3127.
41. Kawai N, Ikematsu, Iwaki N, et al. Zanamivir treatment is equally effective for both influenza A and influenza B (letter). Clin Infect Dis 2007; 44:1666.
42. FDA. Safety: Relenza (zanamivir) inhalation powder. 2009. Available at: http//:www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm186081 (Accessed October 11, 2013).
43. Cass LMR, Efthymiopoulas C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration in healthy volunteers. Clin Pharmacokinet 1999; 36(Suppl 1): 1-11.
44. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282-9.
45. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20: 337-49.
46. Cass LM, Gunawardena KA, Macmahon MM, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000; 94: 166-73.
47. Kim aW-Y, Suh GY, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Ag Chemother 2011; 55: 5703-5709.
48. Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: Predictions from modeling of human infections. J Infect Dis 2012; 205: 1642-5.
49. Matheson NJ, Harnden AR, Perera R, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews 2007(1):CD002744. DO1.10.1002/14651858.CD002744.pub2.
50. Falagas ME, Koletsi PK, Vouloumanon EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: A meta-analysis of randomized, controlled trials. J Antimicrob Chemother 2010; 65: 1330-46.
51. McGeer A, Green KA, Plevneski A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568-75.
52. Hayden FG. Influenza antivirals: Challenges and future directions. Plenary presentation. Options for the Control of Influenza VII. Hong Kong, SAR China, 3-7 September 2010. Available at: www.controlinfluenza.com/webcasts/ optionsvii (Accessed October 11, 2013).
53. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A infection. Antimicrob Ag Chemother 1999; 43: 1616-20.
54. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza (letter). N Engl J Med 2010; 362: 88-9.
55. Dulak DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50: 1493-6.
56. Fraay PLA, van der Vries E, Beersma MFC, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011; 204: 777-82.
57. CDC. Updated Recommendations for the use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 season. Available at: http://www.cdc.gov/h1n1flu/ recommendations.htm. (Accessed October 11, 2013)
58. Aoki FY, Macleod MD, Paggiaro P, et al; on behalf of the IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-9.
59. American Academy of Pediatrics. Influenza. In: Pickering LR, Baker CJ, Kimberlin DW, Long SS. Red Book 2012 Report of the Committee on Infectious Diseases, 29th edn. Elk Grove Village, IL. American Academy of Pediatrics 2012, pp 439-53.
60. World Health Organization. Vaccines against influenza WHO position paper. Wkly Epidemiol Rec 2012; 87: 461-76.
61. Moore DL, Vaudry W, Scheifele DW, et al. Surveillance for influenza admissions among children hospitalized in Canadian Immunization Monitoring Program ACTive centers, 2003-2004. Pediatrics 2006; 118:e610-9.
62. Centers for Disease Control and Prevention. Influenza-associated pediatric deaths - United States, September 2010-August 2011. MMWR Morb Mort Wkly Rep 2011; 60: 1233-8.
63. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: A 25-year prospective study. J Infect Dis 2002; 185: 147-52.
64. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: Systematic review and meta-analysis of randomized controlled trials. BMJ 2009; 3339:b3172. doi:10.1136/BMJ.b3172.
65. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis 2001; 20: 127-33.
66. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age. A randomized controlled trial. Clin Infect Dis 2010; 51: 887-94.
67. Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenzainfected children with asthma. Pediatr Infect Dis 2005; 24: 225-32.
68. Kitching A, Roche A, Balasegaram S, et al. Oseltamivir adherence and side effects among children in three London schools affected by influenza A (H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill 2009; 14:19287.
69. Barr CE, Schulman K, Iacuzio D, et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007; 23: 523-31.
70. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124: 170-8.
71. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenzarelated complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008; 9: 151-61.
72. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2010; 29:195-8
73. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202: 563-6.
74. WHO. Guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. Revised February 2010. Part I. Recommendations Available at: http://www. who.int/csr/resources/publications/ swineflu/h1n1-guidelines- pharmaceutical-mngt.pdf (Accessed October 11, 2013).
75. Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Mork Mort Wkly Rep 2011: 60(RR01);1-24
76. Hackett S, Hill L, Patel J, et al. Clinical characteristics of pediatric H1N1 admissions in Birmingham, UK. Lancet 2009; 374:605.
77. Allen U, Doucette K, Bow E. Guidance on the management of pandemic H1N1 infection in immunocompromised individuals. Available at: http://www.ammi.ca/ pdf/guidelineh1N1.pdf (Accessed October 11, 2013).
78. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11: 100-5.
79. O'Riordan S, Barton M, Yau Y, et al. Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. Can Med Assoc J 2010; 182: 33-44.
80. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997; 102(3A): 2-9.
81. Gooskens J, Jonges M, Claas, EC, et al. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drugresistant viruses. J Infect Dis 2009; 199: 1435-41.
82. Cohen-Daniel L, Zakay-Rones Z, Resnick IB, et al. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient. J Clin Virol 2009; 44: 138-40.
83. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133-7.
84. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309: 13-17.
85. He X-S, Draghi M, Mahmood K, et al. T cell-dependent production of IFN-γ by NK cells in response to influenza A virus. J Clin Invest 2004; 114: 1812-19.
86. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.
87. American Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LR, Baker CJ, Kimberlin DW, Long SS. Red Book 2012 Report of the Committee on Infectious Diseases, 29th edn. Elk Grove Village, IL. American Academy of Pediatrics 2012, p 81.
88. Kumar D, Michaels MG, Morris M, et al. A Multicenter study of outcomes from pandemic influenza A/H1N1 infection in solid organ transplant recipients. Lancet Infect Dis 2010; 10: 521-6.
89. Dodds L, McNeil SA, Fell SB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. Can Med Assoc J 2007; 176: 463-8.
90. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303: 1517-25.
91. Mertz D, Kim KH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: Systematic review and metaanalysis. BMJ 2013; 347:f5061. doi:10.1136/bmj.f5061
92. Pierce M, Kurinczuk JJ, Spark P, et al. Perinatal outcomes after maternal 2009/H1N1 infection: National cohort study. BMJ 2011;342:d3214. doi:10.1136/bmj.d3214.
93. Greer LG, Leff RD, Laibi-Rogers V, et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204S89-S93.
94. Greer LG, Leff RD, Laibl-Rogers V, et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol 2011; 204:524.e1-4.
95. Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. New Engl J Med 2010; 362: 27-35.
96. Tanaka T, Nakajima K, Murashima A, et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding mothers. Can Med Assoc J 2009; 181: 55-8.
97. Donner B, Nianjan V, Hoffmann G. Safety of oseltamivir in pregnancy: A review of preclinical and clinical data. Drug Safety 2010; 33: 631-42.
98. Thorner AR. Treatment of pandemic H1N1 influenza ('swine influenza'). Up To Date. Available at: www.uptodate.com (Accessed October 11, 2013).
99. Centers for Disease Control and Prevention. Interim Guidance for Correctional and Detention Facilities on Novel Influenza A (H1N1) Virus. Available at: http://www.cdc.gov/h1n1flu/guidance/ correctional-facilities.htm (Accessed October 11, 2013).
100. Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36(Suppl 1): 51-58.
101. Hui CPS, McDonald NE; Infectious Diseases and Immunization Committee, Canadian Paediatric Society. The use of influenza vaccine in children with egg allergies. Paediatr Child Health 2011; 16: 491-2.